Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$72.56 USD
-0.95 (-1.29%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $72.58 +0.02 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Price, Consensus and EPS Surprise
GILD 72.56 -0.95(-1.29%)
Will GILD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GILD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GILD
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know
GILD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bristol Myers (BMY) Loses 20.5% YTD: Should You Retain or Fold?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Other News for GILD
Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia
UN urges Gilead to "make history" with game-changing HIV drug
Here are Big Pharma’s leading blockbuster makers
Jefferies Sticks to Their Buy Rating for Gilead Sciences (GILD)
Check Out What Whales Are Doing With GILD